Feller A C, Parwaresch M R, Lennert K
Cancer. 1983 Nov 1;52(9):1609-12. doi: 10.1002/1097-0142(19831101)52:9<1609::aid-cncr2820520912>3.0.co;2-h.
The authors have recently provided evidence for a restricted occurrence of the enzyme dipeptidylaminopeptidase IV (DAP IV) in normal human Tmu lymphocytes as far as blood and bone marrow cells are concerned. In this report, this issue has been extended to cases of chronic lymphocytic leukemia (CLL) along with T-monoclonal antibodies of OKT series (OKT4, OKT8) and Fc receptors for IgM (Tmu) and IgG (Tgamma). Seven of eight cases of T-CLL were DAP IV-positive, whereas all B-CLL cases like normal B-cells were invariably enzyme-negative. Parallel studies with OKT antibodies and Fc receptors showed that the cases positive to DAP IV also revealed OKT4 reactivity and, to some extent, Fc IgM receptor. In a single DAP IV-negative T-CLL with azurophilic granules, the leukemic cells were shown to be reactive for OKT8 and bore Fc IgG receptor. It was inferred that DAP IV represents a reliable marker for T-CLL derived from the OKT4 and Tmu positive subsets of T-lymphocytes, which encompasses the T-helper cell cohort.
就血液和骨髓细胞而言，作者最近提供了证据，证明二肽基氨基肽酶IV（DAP IV）在正常人Tmu淋巴细胞中的出现有限。在本报告中，这个问题已扩展到慢性淋巴细胞白血病（CLL）病例，以及OKT系列的T单克隆抗体（OKT4、OKT8）和IgM（Tmu）及IgG（Tγ）的Fc受体。8例T-CLL中有7例DAP IV阳性，而所有B-CLL病例如正常B细胞一样均为酶阴性。与OKT抗体和Fc受体的平行研究表明，DAP IV阳性的病例也显示出OKT4反应性，并在一定程度上显示出Fc IgM受体。在1例有嗜天青颗粒的DAP IV阴性T-CLL中，白血病细胞显示对OKT8有反应，并带有Fc IgG受体。据推断，DAP IV是源自T淋巴细胞的OKT4和Tmu阳性亚群（包括T辅助细胞群）的T-CLL的可靠标志物。
